Patient Activation Is a State, Not a Campaign.

Activation is what patients can understand, decide, and sustain. A campaign can create attention. It cannot create that state by itself.

Activation is a state, not a personality type.

The Patient Activation Measure describes activation through knowledge, skill, confidence, and the ability to maintain action under stress. In clinical research, that idea must be applied carefully. A patient's activation level is not a permanent label and never determines human worth, eligibility, or the right to receive support.

Activation changes as the study changes. A patient may feel prepared during an introductory call and less prepared after seeing the visit calendar, transportation demand, randomization, or caregiver burden. The operating question is not whether the patient is activated. It is what conditions currently support or weaken informed participation.

Engagement activity can rise while activation stays flat.

Email opens, video views, completed forms, and returned calls show that an interaction occurred. They do not establish that the patient understands the study, sees participation as feasible, or can carry the decision into daily life. Activity can therefore look healthy while readiness remains fragile.

Useful activation evidence is closer to behavior and comprehension: whether the patient can explain the study in their own words, identify likely burdens, name unresolved questions, complete the next step, and describe the support required to continue. These signals reveal the quality of progression rather than the volume of attention.

The trial system shapes the patient's capacity to act.

The original drafts describe activation as something inside the patient. That is only half the picture. Dense materials, unclear handoffs, inaccessible technology, inconvenient schedules, inconsistent answers, and late caregiver involvement can suppress action even when motivation is high.

A readiness-based model treats activation as a shared outcome. Sponsors and sites must make information understandable, decisions voluntary, steps visible, and practical support reachable. The patient's agency remains central, but the system becomes accountable for the conditions under which agency must operate.

Measure activation at the transitions that matter.

Activation should be assessed before high-cost transitions: referral, prescreening, consent, scheduling, randomization, and demanding participation milestones. At each point, teams can ask whether understanding, confidence, feasibility, and support are strong enough for the next step.

The result is a more useful operating signal. Patients who need additional preparation receive it. Patients who decide not to participate can decline clearly. Patients who advance do so with fewer hidden assumptions. That is how activation improves execution without becoming a tool for pressure.

Sources.

1. Hibbard et al., Development of the Patient Activation Measure
2. FDA, Patient-Focused Drug Development Guidance Series
3. CTTI, Patient Group Engagement Recommendations
4. HHS OHRP, The Belmont Report

About the author

Rebecca Schelkun

Vice President, Patient Readiness

Rebecca is Vice President of Patient Readiness at Jumo Health. She combines public health expertise in epidemiology and biostatistics with experience across health equity, patient advocacy, pediatrics, rare disease, and clinical trial strategy. At Jumo, she turns protocol demands and lived experience into education, decision support, and expectation alignment patients can use.